EDX Medical Group Valuation
Is EDX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of EDX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate EDX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate EDX's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EDX?
Key metric: As EDX is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is EDX's PB Ratio? | |
|---|---|
| PB Ratio | n/a |
| Book | UK£0 |
| Market Cap | UK£30.10m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does EDX's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.8x | ||
CUSH CRUSHMETRIC Group | 1.6x | n/a | UK£30.0m |
TLY Totally | 0.5x | 148.7% | UK£18.2m |
KOO Kooth | 2.3x | 11.0% | UK£59.1m |
GENI GENinCode | 2.6x | n/a | UK£7.3m |
EDX EDX Medical Group | n/a | n/a | UK£30.1m |
Price-To-Book vs Peers: Insufficient data to calculate EDX's Price-To-Book Ratio vs. peers for valuation analysis.
Price to Book Ratio vs Industry
How does EDX's PB Ratio compare vs other companies in the European Healthcare Industry?
| 4 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 4 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: Insufficient data to calculate EDX's Price-To-Book Ratio vs. industry for valuation analysis.
Price to Book Ratio vs Fair Ratio
What is EDX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | n/a |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate EDX's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Guerbet
€341.1m
Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.
0ELV
€27.05
7D
-9.8%
1Y
51.3%
Centene
US$29.0b
Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.
0HVB
US$57.48
7D
-5.5%
1Y
-20.8%
Elevance Health
US$92.9b
Operates as a health benefits company in the United States.
0HG8
US$401.96
7D
-5.3%
1Y
-13.1%